As the UAE strengthens its efforts to combat diabetes, healthcare professionals emphasize the importance of early detection, lifestyle changes, and mental health support. With World Diabetes Day highlighting the theme of 'Early Action on Diabetes,' experts stress that timely dia…
This article explores the connection between GLP-1 medications, which aid in weight loss, and the importance of protein intake for preserving muscle mass. It highlights research f…
This article discusses the potential risks associated with discontinuing GLP-1 medications like Ozempic and Zepbound, as outlined by Dr. Frank Dumont. Patients may experience rene…
Dr. Ann Nainan from Medicspot provides a three-step plan to help individuals manage weight regain after discontinuing weight-loss injections such as Wegovy and Mounjaro. She empha…
Researchers at the Weizmann Institute of Science have identified the protein MTCH2, which plays a critical role in determining whether cells burn fat or store it. Disabling this p…
As GLP-1 medications like Ozempic and Mounjaro gain popularity for managing diabetes and obesity, it's crucial to understand their nutritional implications. This article explores…
A recent Phase 3 trial of the experimental obesity medication retatrutide demonstrated an average weight loss of 25% at the highest dose over 80 weeks, along with improvements in…
Eli Lilly's experimental obesity treatment, combining eloralintide and Mounjaro, has demonstrated an average weight loss of 23% in individuals with diabetes, highlighting its pote…
Recent developments in weight-loss medications highlight the potential of amylin-based drugs, which may offer effective weight management with fewer gastrointestinal side effects…
Recent clinical trial data reveals that Retatrutide, a new obesity treatment, resulted in an average weight loss of 25% after 80 weeks and 30% after 104 weeks among participants.…
Eli Lilly's GLP-1 drug retatrutide has demonstrated remarkable efficacy in aiding individuals with Type 2 diabetes to lose up to 60 pounds, or about 23% of their body weight, acco…
Emerging research highlights the potential of microdosing GLP-1 receptor agonists, such as semaglutide, during perimenopause to manage metabolic health. This approach may help add…
Apnimed is preparing for a $160 million initial public offering on the Nasdaq to support the development of its lead therapy for obstructive sleep apnoea (OSA). The Massachusetts-…
As international drug companies ramp up their demands for higher prices, Australia faces a looming crisis in access to essential medications, leading to a farcical standoff that p…